

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Sep 2026

Study of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a clinical trial study

Protocol summary

Study aim

Evaluation of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients

Design

This study is a two arm parallel group, single blinded clinical trial in phase 2 which will be carried out on 68 hospitalized COVID-19 patients. Patients randomly divided into two groups.

Settings and conduct

68 hospitalized COVID-19 patients in Shariati and Imam khomeini hospital and Isfahan medical university will be included in this study.

Participants/Inclusion and exclusion criteria

Inclusion Criteria: COVID-19 patient with confirmed by positive PCR test for SARS-CoV-2 or abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass opacities), Blood oxygen saturation <93%, Respiratory Rate >30 breaths/minute, before connecting to ventilator and intubation. Exclusion criteria: Patients with uncontrolled type I diabetes and blood pressure and positive pro-calcitonin or active infection, and taking any immune-suppressor agents.

Intervention groups

Control group: will receive standard regimen for COVID-19. Methylprednisolone group: will receive standard regimen for COVID-19 plus Methylprednisolone (250mg for 3 days).

Main outcome variables

This clinical trial will be carried out on 68 hospitalized COVID-19 patients in Shariati and Imam khomeini hospital of Tehran and Isfahan medical university, Iran. Patients will be received 250mg methylprednisolone pulse for 3 days. In this study, patients don't know which group of them will use the medicine. Physician and clinicians team know about the medicine and intervention groups.

General information

Reason for update

update the blindness, randomization of the study, sample size and the time of clinical record

Acronym

IRCT registration information

IRCT registration number: **IRCT20200404046947N1**

Registration date: **2020-04-15, 1399/01/27**

Registration timing: **registered_while_recruiting**

Last update: **2020-05-22, 1399/03/02**

Update count: **1**

Registration date

2020-04-15, 1399/01/27

Registrant information

Name

Abdolrahman Rostamian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2691 1458

Email address

arostamian@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-03-28, 1399/01/09

Expected recruitment end date

2020-05-28, 1399/03/08

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Study of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a clinical trial study

Public title

Effect of Methylprednisolone on treatment of COVID-19

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

COVID-19 patient confirmed by positive PCR test for SARS-CoV-2 or abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass opacities), Blood oxygen saturation <93%, Respiratory Rate >30 breaths/minute, before connecting to ventilator and intubation.

Exclusion criteria:

Patients with uncontrolled type I diabetes, blood pressure, positive pro-calcitonin, active infection, and taking any immune-suppressor agents, will exclude from the study.

Age

From **18 years** old

Gender

Both

Phase

2

Groups that have been masked

- Participant

Sample size

Target sample size: **68**

Randomization (investigator's opinion)

Randomized

Randomization description

Block randomization

Blinding (investigator's opinion)

Single blinded

Blinding description

In this study patients don't know which group of them will use the medicine. Physician and clinicians team know about the medicine and intervention groups.

Placebo

Not used

Assignment

Parallel

Other design features

This study is double blinded clinical trial in phase 2 which will be carried out on 68 hospitalized COVID-19 patients. Patients randomly divided into two groups. Control group and treatment group which received of medicine (250 mg methylprednisolone pulse for 3 days). Clinical signs of patient including heart rate, blood pressure body temperature, O2 saturation, laboratory tests result (CBC, ESR, CRP, VBG, IL-6, Ferritin, Troponin, D-dimer) will be recorded before and after treatment (after 3 days of treatment and at discharge time). In addition, dyspnea, cough, GI Symptom, myalgia, chest pain and BORG Score will be assessed before and after treatment (after 3 days of treatment and at discharge time). Need an oxygen therapy (nasal Cannula, mask Oxygen, reserve Mask, NIV and invasive ventilation) will also be recorded before and

after treatment (after 3 days of treatment and at discharge time).

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Vice-Chancellor in Research Affairs Tehran University of Medical Science

Street address

Central Building of Tehran University of Medical Sciences, Qods St., Keshavarz Blvd.

City

Tehran

Province

Tehran

Postal code

1416753955

Approval date

2020-03-27, 1399/01/08

Ethics committee reference number

IR.TUMS.VCR.REC.1399.054

Health conditions studied**1****Description of health condition studied**

COVID-19 disease

ICD-10 code

U07.2, U07

ICD-10 code description

COVID-19

Primary outcomes**1****Description**

Radiographic features Findings

Timepoint

Before and at discharge time only in patients agreed to give informed consent

Method of measurement

CT scan

2**Description**

Mortality rate

Timepoint

Before and after

Method of measurement

Observation

3

Description

O2 saturation

Timepoint

Before and after (by 3 days of treatment and at discharge)

Method of measurement

Pulse Oximeter

4

Description

Need an oxygen therapy

Timepoint

Before and after (at day 3 and discharge time)

Method of measurement

clinical

Secondary outcomes

1

Description

laboratory tests

Timepoint

Before and after (at day 3, and discharge time)

Method of measurement

Para-clinical

Intervention groups

1

Description

Intervention group: Patients hospitalized with COVID-19 disease who in addition to their standard treatment will be received 250mg/day Methylprednisolone for 3 days.

Category

Treatment - Drugs

2

Description

Control group: Patients hospitalized with COVID-19 disease who are received standard treatment

Category

Treatment - Other

Recruitment centers

1

Recruitment center**Name of recruitment center**

Shariati Hospital

Full name of responsible person

Ahmadreza Jamshidi

Street address

Shariati Hospital, Jalal-e-Al-e-Ahmad Hwy

City

Tehran

Province

Tehran

Postal code

1313514117

Phone

+98 21 8822 0065

Email

jamshida@sina.tums.ac.ir

2

Recruitment center**Name of recruitment center**

Imam khomeini Hospital

Full name of responsible person

Maryam Edalatifard

Street address

Imam Khomeini Hospital Complex, Tohid Squire

City

Tehran

Province

Tehran

Postal code

1419733141

Phone

+98 21 6658 1594

Email

M-edalatifatd@tums.ac.ir

3

Recruitment center**Name of recruitment center**

Khorshid Hospital

Full name of responsible person

Zohre Naderi

Street address

Khorshid Hospital, Ostandari St,

City

Isfahan

Province

Isfahan

Postal code

8145831451

Phone

+98 31 3303 3740

Email

Zo698@hotmail.com

Sponsors / Funding sources

1

Sponsor**Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

mohammad ali sahraian

Street address

Central Building of Tehran University of Medical Sciences, Qods St., Keshavarz Blvd

City

Tehran
Province
 Tehran
Postal code
 1416753955
Phone
 +98 21 8163 3685
Email
 vcr@tums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
 Yes
Title of funding source
 Tehran University of Medical Sciences
Proportion provided by this source
 100
Public or private sector
 Public
Domestic or foreign origin
 Domestic
Category of foreign source of funding
 empty
Country of origin
Type of organization providing the funding
 Academic

Person responsible for general inquiries

Contact
Name of organization / entity
 Tehran University of Medical Sciences
Full name of responsible person
 Abdorahman Rostamian
Position
 Assistant professor
Latest degree
 Subspecialist
Other areas of specialty/work
 Internal Medicine
Street address
 Shariati Hospital, Jalal-e-Al-e-Ahmad Hwy
City
 Tehran
Province
 Tehran
Postal code
 1411713135
Phone
 +98 21 6119 2756
Email
 arostamian@tums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
 Tehran University of Medical Sciences
Full name of responsible person
 Mahdi Mahmoudi

Position
 Associate professor
Latest degree
 Ph.D.
Other areas of specialty/work
 Immunology
Street address
 Shariati Hospital, Jalal-e-Al-e-Ahmad Hwy
City
 Tehran
Province
 Tehran
Postal code
 1411713135
Phone
 +98 21 8822 0065
Email
 mahmoudim@tums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
 Tehran University of Medical Sciences
Full name of responsible person
 Maryam Akhtari
Position
 Consultant
Latest degree
 Ph.D.
Other areas of specialty/work
 Immunology
Street address
 Shariati Hospital, Jalal-e-Al-e-Ahmad Hwy
City
 Tehran
Province
 Tehran
Postal code
 1411713135
Phone
 +98 21 8822 0067
Email
 m.akhtari@ut.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
 Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
 Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
 Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
 Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
 Yes - There is a plan to make this available
Analytic Code

Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
It will be published as an article
When the data will become available and for how long
After printing the article
To whom data/document is available
All medical professionals and scientists

Under which criteria data/document could be used
There is no restriction on access to information
From where data/document is obtainable
Dr. Abdorahman Rostamian, Tehran University of Medical Science
What processes are involved for a request to access data/document
Refer to the project supervisor
Comments